Faisabilité de l’administration du carfilzomib en hospitalisation à domicile dans la prise en charge du myélome multiple (étude Carfil-HAD)
Bulletin du Cancer · 2026
DOI: 10.1016/j.bulcan.2025.09.005 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bulletin du Cancer, 2026. Verfasst von Mohamed Touati und 16 weiteren Autor:innen. Beteiligte Einrichtung: Hématologie clinique et thérapie cellulaire, CHU Dupuytren, Limoges, France; Service d'hospitalisation à domicile (HAD), CHU Dupuytren, Limoges, Fran…. Hauptthemen laut MEDLINE: Multiple Myeloma, Oligopeptides, Home Infusion Therapy, Antineoplastic Agents. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Amgen Inc.
Abstract (Originalsprache)
The growing number of cancer cases induces increasing pressure on oncology and hematology departments, creating the need for alternatives such as hospitalization at home (HAH). The Carfil-HAD pilot study aimed to assess the feasibility and safety of administering short-duration intravenous carfilzomib infusions at home for the treatment of multiple myeloma. Among the 17 patients included, 15 received 128 infusions of Carfilzomib under a combined Outpatient Hospital (OH)/HAH scheme, are evaluable. Deviations from standard operating procedures were monitored, quality of life and satisfaction were evaluated, and a cost-effectiveness analysis compared the mixed OH/HAH model to exclusive OH care. The results confirmed feasibility: of 128 infusions, 42 were performed in OH and 86 in HAH without serious incident or interruption of care, with 96% of deviations classified as minor. Quality of life is not affected by the mixed care organization, and patient satisfaction was very high. From an economic perspective, the OH/HAH model generated savings of €610 per treatment cycle, nearly half the cost of hospital-based care. In conclusion, intravenous administration of carfilzomib in HAH is feasible and safe. This organization could be applied to other oncological therapies to offer a wider range of outpatient's care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hématologie clinique et thérapie cellulaire, CHU Dupuytren, Limoges, France; Service d'hospitalisation à domicile (HAD), CHU Dupuytren, Limoges, France. Electronic address: mohamed.touati@chu-limoges.fr.
- Hématologie, CH de Brive, Brive-la-Gaillarde, France.
- Pharmacie à Usage Intérieur (PUI), CHU Dupuytren, Limoges, France.
- Hématologie clinique et thérapie cellulaire, CHU Dupuytren, Limoges, France.
- Pharmacie à Usage Intérieur (PUI), CH de Brive, Brive-la-Gaillarde, France.
- Service d'hospitalisation à domicile (HAD), relais santé par Relais santé, Hospitalisation à domicile (HAD), Brive-la-Gaillarde, France.
Förderung
- Amgen Inc
Zitieren
APA
Touati, M., Villesuzanne, C., Maillan, G., Dmytruk, N., Streicher, C., Brillat, C., Bompart, F., Chauvet, C., Tisseuil, C., Sardin, S., Perraud, A., Bastide, S., Lamarsalle, L., Massoulard-Gainant, A., Girault, S., Roussel, M., & Moreau, S. (2026). Faisabilité de l’administration du carfilzomib en hospitalisation à domicile dans la prise en charge du myélome multiple (étude Carfil-HAD). Bulletin du Cancer. https://doi.org/10.1016/j.bulcan.2025.09.005
Vancouver
Touati M, Villesuzanne C, Maillan G, Dmytruk N, Streicher C, Brillat C, et al. Faisabilité de l’administration du carfilzomib en hospitalisation à domicile dans la prise en charge du myélome multiple (étude Carfil-HAD). Bulletin du Cancer. 2026. doi:10.1016/j.bulcan.2025.09.005
BibTeX
@article{Touati2026,
author = {Touati, Mohamed and Villesuzanne, Camille and Maillan, Gaëlle and Dmytruk, Natalia and Streicher, Caroline and Brillat, Catherine and Bompart, Frederica and Chauvet, Cindy and Tisseuil, Chantal and Sardin, Sophie and Perraud, Aurélie and Bastide, Sophie and Lamarsalle, Ludovic and Massoulard-Gainant, Aude and Girault, Stéphane and Roussel, Murielle and Moreau, Stéphane},
title = {Faisabilité de l’administration du carfilzomib en hospitalisation à domicile dans la prise en charge du myélome multiple (étude Carfil-HAD)},
journal = {Bulletin du Cancer},
year = {2026},
doi = {10.1016/j.bulcan.2025.09.005}
}
EUVIMED